New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
09:03 EDTBTXBioTime unit expands clinical development of bladder cancer test
BioTime and its subsidiary OncoCyte announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the U.S., has received Institutional Review Board approval at multiple sites and should begin enrolling patients within the next week. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial is designed to expand the potential use of the PanC-Dx bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months. The goal of the current clinical trial is to compare the performance of OncoCyte’s proprietary PanC-Dx bladder cancer markers to the performance of cystoscopy.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
09:26 EDTBTXBioTime clinical-grade hES cell lines to be used in planned CIRM-funded study
BioTime announced that the clinical-grade human Embryonic Stem, or hES, cell lines from BioTime’s wholly-owned subsidiary ES Cell International Pte, will be used by UC Irvine scientist Dr. Leslie Thompson to continue her promising research in the use of stem cells to treat Huntington’s disease under a $5M grant from the California Institute for Regenerative Medicine, or CIRM. The CIRM grant will further support a collaboration between ESI and UC Davis’s good-manufacturing-practice, or GMP, laboratory for the creation of the GMP grade cells needed in Dr. Thompson’s preclinical and potentially subsequent clinical studies. This collaboration is an example of BioTime’s strategy to leverage collaborations and potentially generate future revenues by placing its hES cells in a wide array of medical applications that BioTime could not otherwise address with its own resources. ESI provides its hES cells as both inexpensive research-grade cells through its ESI BIO division and as GMP-compliant clinical grade cells for translation into clinical applications, allowing researchers to conduct research with hES cells that can also be used in the clinic.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use